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General Perspectives on Risk and 
Effect on Intervention 
The continuing increase in the prevalence of coronary 
artery disease coupled with increasing evidence for the clinical 
and economic benefits of prevention provides the clinician with 
an opportunity oimprove patient outcomes. There are over 7 
million Americans with diagnosed coronary artery disease (1); 
the challenge is to develop the tools and information to focus 
our efforts effectively. Definitive evidence xists that meaning- 
ful changes in mortality and morbidity may be achieved through 
prevention strategies inpatients with established cardiovascular 
disease (2,3), and a strong rationale xists in high risk patients 
without documented vascular disease. Decisions made during 
every patient-physician contact form a small but incrementally 
important portion of risk intervention during the life of a person 
who has or is at risk for the development of coronary artery 
disease. Thus, a focused approach to preventing coronary events 
using risk stratification begins with the initial patient encounter 
and is continually refined as additional information is acquired 
and as the disease process progresses. 
For the same reasons that intensive intervention may be 
most cost-effective in patients with established cardiovascular 
disease (4), the concept hat identification of risk level can 
provide a guide to the intensity of preventive measures i  
attractive. As the number of cardiac risk factors increases, the 
rise in associated risk may be multiplicative. In this task force 
we review the available information about level of risk as a 
function of various types of risk factors in the sequence in 
which they become available to the clinician (identification of 
individual risk factors is reviewed in previous task forces). An 
attempt is then made to provide a model for assigning patients 
to levels of risk in a manner that could be helpful in the 
development of prevention strategies. 
Fundamentals of risk prediction. Risk prediction has been 
described as an effort o predict he future from knowledge of 
the past (5). This activity has always been regarded as a 
fundamental component of the role of health care providers, 
but the methods of assessing risk have often been arbitrary and 
informal. Clinicians have tended to use heuristics, or "rules of 
thumb," to identify patients at high risk or low risk of poor 
outcomes, to advise the patient and to develop treatment 
strategies. Unfortunately, this approach suffers from a lack of 
consensus about he definition of high and low risk, an inability 
to determine the accuracy of individualized predictions of risk 
in practice and the difficulty of synthesizing multiple risk 
characteristics into a specific estimate of risk for the individual. 
This last problem is particularly troublesome considering that 
multiple risk factors are known, their assessment can be 
expensive, and they overlap substantially. In contrast to this 
heuristic approach, selected research groups, exemplified by 
the Framingham Study, have systematically and scientifically 
estimated the risks of cardiovascular morbid events and mor- 
tality with mathematical functions (6,7). These functions have 
been shown to have validity and applicability to populations 
beyond their original cohorts (8-10). While substantial 
progress has been made in the science of risk prediction 
(11-14), the available methods are continuing to evolve (12). 
What are we trying to predict? The perspective of this 
section will be that the goal of clinical risk prediction is to 
provide the clinician and the patient with a logical estimate 
that an important deleterious clinical event will occur. The 
most important outcome isdeath. However, an understanding 
of the future risk of nonfatal clinical outcomes, particularly 
myocardial infarction, stroke, symptomatic heart failure, hos- 
pitalization for unstable angina s well as changes in functional 
capacity and overall quality of life, must be recognized as a 
critical element of risk evaluation. These events inevitably are 
intermingled with the need for and the use of revascularization 
procedures ( urgical and percutaneous), which carry an early 
increase but a possible later decrease in the risk of later 
coronary artery disease vents. Finally, the economic onse- 
quences of coronary artery disease are of increasing concern to 
patients and health care providers. Unfortunately, little infor- 
mation is available about predictors of any of these outcomes 
other than death. 
Why should we predict? Differential risk stratification 
within the traditional risk factors influences three partners of 
medical delivery: physicians, patients and insurers. 
Physicians. Appropriate physician care of patients with 
coronary artery disease depends on the ability to make indi- 
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vidual decisions based on accurate risk discrimination; this is 
fundamental toensure quality care. In addition, as the number 
of clinical pathways proliferates, this information will be 
crucial for implementation a d variance analysis. 
Patients. Patients are becoming more informed consumers 
of health care. Having the patient as an active participant in 
informed clinical decision making can improve outcomes, utiliza- 
tion and quality of life (15); for patients with coronary artery 
disease, this process is grounded in accurate risk assessment a
every point in the decision tree. Patient involvement in care, 
based on accurate risk assessment and the knowledge of risk 
reduction probabilities, can also be a powerful motivation for 
drug, diet and exercise compliance and other life-style changes. 
Ultimately, these data affect family and economic planning for the 
future, which cannot be approached without knowledge based on 
the accurate prediction of risk and its negative consequences. 
Insurers. Future benefit coverage decisions about new tech- 
nologies, drugs and interventions will depend on the ability to 
assess risk and apply new actuarial models for care delivery. 
Cost-effective interventions that reduce risk will be supported; 
activities that do not affect outcome or quality of life will not be 
supported. 
Multifactorial nature of risk. Risk factors are additive and 
(in some cases) interactive. Predicting the risk of a clinical event 
in a patient with known disease requires an understanding ofhow 
biologic and clinical factors interact o provide an overall risk. 
Mathematical modeling is necessary to provide a quantitative 
assessment of the magnitude of the interactive ffect. 
Discussion concerning risk stratification of patients with 
coronary artery disease has traditionally focused on a variety of 
noninvasive and invasive diagnostic strategies. It should be 
appreciated that appropriate risk stratification should not be 
delayed until after the results of specialized noninvasive or 
invasive tests are known. Rather, test results hould be consid- 
ered for their incremental value beyond the provider's pretest 
clinical impression of risk. This impression is first formed with 
the patient's history, physical examination and electrocardio- 
gram (ECG). After all of this information is quantified, the 
value of additional testing in assessing risk can be determined. 
Quality of studies. The ideal information to develop sta- 
tistical models to assess risk in patients with known coronary 
artery disease would include a complete assessment of the 
population: demographics, medical history, physical examina- 
tion, coronary anatomy, left ventricular function, laboratory 
measurements and provocative or functional testing. Obvi- 
ously, no single study contains this ideal information set; 
accordingly, this effort will attempt o synthesize information 
from a variety of sources to provide an overview of risk. 
The prognoses of patients who have or who are at risk of 
developing coronary artery disease have been determined from 
multiple sources, including population-based studies, multi- 
center trials, multicenter and single-center registries and indi- 
vidual investigators or groups (5). The Framingham Study 
provides a good example of population-based incidence and 
prevalence data; however, it does not include detailed infor- 
mation about invasive or noninvasive testing. Single-center 
registries are frequently more complete than multiple-site 
registries, although multiple-site registries are more generaliz- 
able. One of the main criticisms of the multicenter clinical trial 
is that only a portion of patients, for a variety of reasons, enter 
the trial. Registry data, such as those from the Coronary Artery 
Surgery Study (CASS) (16) and the Duke Databank for 
Cardiovascular Disease (17,18), provide a structured way of 
examining prognostic data but do not limit patient enrollment. 
The practical assessment of risk will focus on statistical models 
developed in the Framingham Study and the Duke Databank, 
since these models have been validated in independent popu- 
lations. Other excellent models yielding comparable r sults are 
also available. 
Risk Prediction in People Free of 
Coronary Artery Disease 
Multivariable risk assessment. The first level of risk pre- 
diction and stratification is for those free of coronary artery 
disease but who might be at high risk for coronary artery 
disease due to modifiable risk factors, such as hypertension, 
hyperlipidemia and smoking, or immutable factors, such as age 
and gender. To develop a method for predicting risk in this 
population, the Framingham Study generated a mathematical 
model (an accelerated-failure model) that can be used to 
predict he probability of developing a clinical manifestation f
coronary artery disease based on a patient's profile of standard 
risk factors (19). Further, the Framingham Study, with the 
American Heart Association, generated from this function a 
simple "Coronary Heart Disease Risk Factor Prediction Chart" 
for producing 5- and 10-year predictions of the probability of 
developing clinical evidence of coronary artery disease. This 
chart is presented in Table 1. 
To use Table 1, data on eight risk factors are needed: 
gender, age, high density lipoprotein (HDL), total serum 
cholesterol, rest systolic blood pressure, cigarette smoking (yes 
or no), diagnosis of diabetes (yes or no) and the presence or 
absence of left ventricular hypertrophy obtained from the ECG 
(yes or no). Depending on the values and categories of these 
risk factors, points are assigned. The points are then totaled, 
and 5- and 10-year probabilities corresponding to individual 
risk are obtained. The 10-year probability can be compared 
with the gender- and age-specific average 10-year probability 
(risk) obtained empirically from the Framingham population. 
The ratio of the estimated probability to the Framingham age- 
and gender-specific risk can be used as an estimate of the 
patient's risk relative to an "average" individual of the same 
gender and age. These relative risk estimates have been shown 
to be valid when the Framingham functions are applied to 
different populations (9,20,21). 
For example, a60-year old man with an HDL cholesterol f 
35 mg/dl, total cholesterol f 240 mg/dl, systolic blood pressure 
of 160 mm Hg and who smokes cigarettes, is diabetic and has 
no left ventricular hypertrophy on the ECG would be assigned 
14 points for being 60 years old and male and 4, 3, 4, 4, 3 and 
0 points, respectively, for the HDL cholesterol, total choles- 
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Table 1. Coronary Heart Disease Risk Factor Prediction Chart: Patients Without Known Coronary Artery Disease 
1. Find Points for Each Risk Factor: 
Women Men 
Age Age Age Age HDL-C Total-C SBP 
(yr) Pts (yr) Pts (yr) Pts (yr) Pts (mg/dl) Pts (mg/dl) Pts (mm Hg) Pts Other Pts* 
30 -12 47-48 5 30 -2  57-59 13 25-26 7 139-151 
31 -11 49-50 6 31 -1 60-61 14 27-29 6 152-166 
32 -9  51-52 7 32-33 0 62-64 15 30-32 5 16%182 
33 -8  53-55 8 34 1 65-67 16 33-35 4 183-199 
34 -6  56-60 9 35-36 2 68-70 17 36-38 3 200-219 
35 -5  61-67 10 37-38 3 71-73 18 39-42 2 220-239 
36 - 4 68 -74 11 39 4 74 19 43- 46 1 240 -262 
37 -3  40-41 5 4%50 0 263-288 
38 -2  42-43 6 51-55 -1 289-315 
39 -1 44-45 7 56-60 -2  316-330 
40 0 46-47 8 61-66 -3  
41 1 48-49 9 67-73 -4  
42-43 2 50-51 10 74-80 -5  
44 3 52-54 11 81-87 -6  
45-46 4 55-56 12 88-96 -7  
-3  98-104 -2  Cigarettes 
-2  105-112 -1 Diabetic (male) 
-1  113-120 0 Diabetic (female) 
0 121-129 1 ECG-LVH 
1 130-139 2 
2 140-149 3 
3 150-160 4 
4 161-172 5 
5 173-185 6 
6 
2. Sum Points for All Risk Factors (subtract minus points from total): 
- - + - - + - - + - - + -  
Age HDL-C Total-C SBP Smoker + Diabete------~ + ECG-LVH Point total 
3. Look Up Risk Corresponding to Point Total: 
4. Compare With Average 
10-Year Risk: 
Probability Probability 
Pts 5 yr 10 yr Pts 5 yr 10 yr Pts 5 yr 10 yr Pts 5 yr 10 yr Age (yr) Women Men 
--<-1 <1% <2% 10 2% 6% 19 8% 16% 28 19% 33% 30-34 <1% 3% 
2 1% 2% 11 3% 6% 20 8% 18% 29 20% 36% 35-39 <1% 5% 
3 1% 2% 12 3% 7% 21 9% 19% 30 22% 38% 40-44 2% 6% 
4 1% 2% 13 3% 8% 22 11% 21% 31 24% 40% 45-49 5% 10% 
5 1% 3% 14 4% 9% 23 12% 23% 32 25% 42% 50-54 8% 14% 
6 1% 3% 15 5% 10% 24 13% 25% 55-59 12% 16% 
7 1% 4% 16 5% 12% 25 14% 27% 60-64 13% 21% 
8 2% 4% 17 6% 13% 26 16% 29% 65-69 9% 30% 
9 2% 4% 18 7% 14% 27 17% 31% 70-74 12% 24% 
*Zero points for each "no." ECG-LVH = electrocardiographic left ventricular hypertrophy; HDL-C = high density lipoprotein cholesterol; pts = patients; SBP = 
systolic blood pressure; Total-C = total cholesterol. 
terol, systolic blood pressure, smoking, presence of diabetes 
and lack of left ventricular hypertrophy. This yields a total of 
32 points, which corresponds to an estimated 10-year proba- 
bility of having a clinical manifestation of coronary artery 
disease of 42%. The average 10-year isk for 60-year old men 
from the Framingham Study population was 21%. The present 
subject has a relative risk of 2.00 (42% - 21%) or a 100% 
higher risk. 
Given the 5- or 10-year probability estimates and the status 
of the individual risk factors in conjunction with existing 
guidelines, the physician can determine the seriousness of the 
patient's risk and plan intervention strategies. Further, the 
physician can estimate the potential effect of a successful 
intervention. For example, in the previous example, if the 
patient's HDL cholesterol could be elevated to 45 mg/dl, total 
cholesterol reduced to 200 mg/dl, systolic blood pressure 
reduced to 120 mm Hg and the smoking stopped, then the 
10-year probability would decrease to 16%, an absolute reduc- 
tion of 26% (42% - 16%), or a relative reduction of 62% 
[100(42 - 16)/42]. This estimate of the potential success of the 
intervention should be viewed only as a guide. In the applica- 
tion of any intervention, there are factors not necessarily 
captured in the mathematical functions, and only a random- 
ized trial can determine the net effect of an intervention. 
Risk associated with fibrinogen. Thrombogenic compo- 
nents contribute to the risk of atherosclerosis and to its clinical 
manifestations. One example from the Framingham Study and 
other studies is the significant role of fibrinogen as a risk factor 
for the development of coronary artery disease (22). Simple 
approximate multiplicative adjustments to the probabilities 
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Table 2. Independent Effect of Fibrinogen: Risk Adjustment 
Multiplication Factor for Probability 
Estimate Obtained From Table 1 
Fibrinogen Level 
(mg/dl) Male Female 
<235 0.83 0.77 
235-335 1.00 1.00 
>335 1.20 1.30 
obtained from Table 1 that incorporate he independent effect 
of fibrinogen are presented in Table 2. 
To illustrate the use of Table 2, consider previous example 
of the 60-year old man used to illustrate the use of Table 1. He 
had a 10-year probability of developing a clinical manifestation 
of coronary artery disease of 42%. If he had a fibrinogen level 
of 350 mg/dl, then using the Table 2, his adjusted probability is 
50.4% (42% × 1.20). 
Consideration of other vascular outcomes. While our ob- 
jective is to focus on the risk of coronary artery disease, and 
not to be inclusive and cover the broader category of vascular 
disease, physicians and patients are concerned about the 
possibility of other outcomes. Risk factors for the development 
of coronary artery disease are also risk factors for other 
vascular events such as stroke. The effects of these risk 
factors--age, diabetes, smoking, cerebrovascular disease, sys- 
tolic blood pressure, atrial fibrillation and left ventricular 
hypertrophy--on the development of stroke have been quan- 
tified by the Framingham Study Group (7,23). In the assess- 
ment of risk and stratification of patients, coronary artery 
disease risk factors may take on a slightly different role for 
other vascular diseases, uch as the role of blood pressure in 
the development of stroke. Further, other variables not of 
immediate concern for one cardiovascular condition (such as 
atrial fibrillation) may take on a major ole for other manifes- 
tations of cardiovascular disease. 
Risk Prediction in Patients With Exist ing 
Coronary Artery Disease 
Standard risk factors. For patients with overt coronary 
artery disease, functions have been developed recently from 
Framingham data for estimating 2-year probabilities of a 
future coronary artery disease event. These functions are 
presented in Tables 3 and 4 for women and men, respectively, 
in a format similar to that of Table 1. While it is important to 
react o the presence of any risk factor, especially the modifi- 
able ones, in a patient with existing coronary artery disease, 
Tables 3 and 4 should be useful for further clarification of the 
role and importance of the traditional risk factors in these 
patients. The variable "cigarette smoking" was not statistically 
significant in men. This apparent anomaly has appeared in 
other studies and probably relates to the fact that the smokers 
who survive the acute period of coronary artery disease are 
younger than surviving nonsmokers. The variables for ECG 
left ventricular hypertrophy and fibrinogen have not yet been 
added to these Framingham functions, but both are highly 
significant, especially left ventricular hypertrophy. High levels 
of fibrinogen (above 310 mg/dl) and the presence of ECG left 
ventricular hypertrophy should be cause for concern. 
These functions do not include an assessment ofsymptoms 
or additional testing and therefore should be considered to be 
only approximate guides to risk prediction. As demonstrated in 
the following sections, knowledge of more detailed informa- 
tion about symptom status, coronary anatomy, left ventricular 
function and stress testing can provide more powerful prog- 
nostic estimates in patients with a previous event. 
Clinical Scenarios and Time-Related Risk 
For the purposes of clinical risk stratification for secondary 
prevention, the patient may be considered to be in one of five 
categories: stable coronary artery disease, unstable angina, 
acute myocardial infarction, post-coronary artery bypass ur- 
gery, or post-percutaneous coronary intervention. The latter 
four categories have in common with stable coronary artery 
disease the presence of the diseased arterial wall, and the 
practitioner must assume that all diseased coronary vessels are 
susceptible toplaque fissuring and subsequent thrombosis. They 
differ from stable coronary artery disease in that condition- 
specific issues arise in secondary prevention. Figure 1 displays 
the time-related risk of future cardiac events as a function of 
time from the event or procedure (24,25). The patient seen at 
the time of discharge after acute myocardial infarction or 
unstable angina is in the midst of a particularly high risk 
period, during which the myocardium is prone to sudden 
electrical instability, and the initially disrupted atherosclerotic 
plaque is susceptible to rethrombosis. After bypass grafting, 
the hazard of graft occlusion due to mechanical or thrombotic 
causes is greatest within the first month to 1 year after 
operation, followed by a low risk period (Fig. 2) (26). After 
angioplasty, atherectomy, Rotablator or stent placement, a 
significant risk of restenosis exists in the first 6 months, which 
subsequently declines exponentially; the obvious impact of 
time as a risk factor and for risk stratification is thus empha- 
sized. This section will focus on secondary prevention i  the 
patient with stable coronary artery disease, with mention of the 
latter four situations where appropriate. 
These categories may be further modified epending on the 
symptomatic status of the patient. For example, those with 
acute ischemic syndromes form a higher isk group than those 
who are asymptomatic. Risk has been similarly categorized in
patients with congestive heart failure symptoms (e.g., New 
York Heart Association functional class). Another high risk 
group is sudden-death survivors, whose short- and long-term 
event risk is much higher than that of other patient populations 
with stable coronary disease. 
Medical History 
Assessment of patient risk in relation to clinical conditions 
emanating from established atherosclerosis depends on basic 
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Table 3. Risk of Coronary Artery Disease Event, Stroke or Cerebrovascular Disease Death in Women 
With Existing Coronary Artery Disease 
Points by HDL-C (mg/dl) 
Age Total-C SBP 
(yr) Points (mg/dl) 25 30 35 40 45 50 60 70 80 (ram Hg) Points 
35 0 160 4 3 3 2 2 1 1 0 0 100 0 
40 1 170 4 3 3 2 2 2 1 1 0 110 0 
45 2 180 4 3 3 2 2 2 1 1 0 120 1 
50 3 190 4 4 3 3 2 2 1 1 1 130 1 
55 4 200 4 4 3 3 2 2 2 1 1 140 2 
60 5 210 4 4 3 3 3 2 2 1 1 150 2 
65 6 220 5 4 4 3 3 2 2 1 1 160 2 
70 7 230 5 4 4 3 3 3 2 2 1 170 3 
75 7 240 5 4 4 3 3 3 2 2 1 180 3 
250 5 4 4 4 3 3 2 2 1 190 3 
260 5 5 4 4 3 3 2 2 1 200 3 
270 5 5 4 4 3 3 2 2 2 210 4 
Other Pts 280 5 5 4 4 3 3 3 2 2 220 4 
Diabetes 3 290 5 5 4 4 4 3 3 2 2 230 4 
Smoking 3 300 6 5 4 4 4 3 3 2 2 240 4 
250 4 
Average 2-yr Risk in Women With CVD 
2-yr 
Tota l  Probability Age Probability 
Points (%) (yr) (%) 
0 0 
2 1 
4 1 
6 1 
8 2 
10 4 
12 6 
14 10 
16 15 
18 23 
20 35 
22 51 
24 68 
26 85 
35-39 <1 
40-44 <1 
45-49 <1 
50 -54 4 
55-59 6 
60 - 64 8 
65-69 12 
70-74 12 
CVD = cerebrovascular disease; other abbreviations as in Table 1. 
data from the history, physical examination, 12-lead ECG and 
appropriate laboratory tests. 
Myocardial infarction. The occurrence of a myocardial 
infarction is a sentinel event in the life of a patient with 
coronary artery disease. After the initial coronary occlusion, 
the risk of death or nonfatal complications is extremely high, 
and this risk diminishes nonlinearly with time (25). This 
time-related risk seems to be a function of the propensity for 
sudden ventricular arrhythmia. It is additive to the risk attrib- 
utable to the amount of left ventricular dysfunction induced by 
the acute event. 
The ECG manifestations of infarction also have an effect on 
risk. Although patients with a non-Q wave myocardial infarc- 
tion have a higher rate of spontaneous reperfusion, smaller 
infarctions and lower in-hospital mortality than those with a 
Q wave myocardial infarction, they tend to have a higher rate 
of late (subsequent) ischemic events (27). 
Treatment that reestablishes Thrombolysis in Myocardial 
Infarction (TIMI) grade 3 coronary blood flow and restores 
patency, whether by thrombolytic agents or direct percutane- 
ous transluminal coronary angioplasty, reduces risk substan- 
tially compared with patients in whom reperfusion has not 
been established (28-31). 
Severity of angina. Stable angina. The clinical history and 
physical examination remain mainstays of the initial evaluation 
of patients with coronary artery disease. A description of 
classic exertional angina provides a prognostic accuracy that is 
hard to exceed with more complex technologies. At the end of 
the initial evaluation, a decision must be made about the 
patient's short-term risk of adverse events, which dictates the 
type and intensity of additional evaluations. Characteristics 
from the initial examination can predict both the extent of 
coronary artery disease and survival (17,18). Anginal symp- 
toms contribute significantly to the prediction of multivessel 
disease and 3-year survival. In fact, the prevalence of multives- 
sel disease increases with age and the occurrence of typical 
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Table 4. Risk of Coronary Artery Disease Event, Stroke or Cerebrovascular Disease Death in Men 
With Existing Coronary Artery Disease 
Points by HDL-C (mg/dl) 
Age Total-C SBP 
(yr) Points (mg/dl) 25 30 35 40 45 50 60 70 80 (ram Hg) 
35 0 160 6 5 4 4 3 2 1 1 0 100 
40 1 170 6 5 5 4 3 3 2 1 0 110 
45 1 180 7 6 5 4 4 3 2 1 1 120 
50 2 190 7 6 5 4 4 3 2 2 1 130 
55 2 200 7 6 5 5 4 4 3 2 1 140 
60 3 210 7 6 6 5 4 4 3 2 1 150 
65 3 220 8 7 6 5 5 4 3 2 2 160 
70 4 230 8 7 6 5 5 4 3 3 2 170 
75 4 240 8 7 6 6 5 4 4 3 2 180 
250 8 7 6 6 5 5 4 3 2 190 
260 8 7 7 6 5 5 4 3 2 200 
270 9 8 7 6 6 5 4 3 3 210 
Other Pts 280 9 8 7 6 6 5 4 4 3 220 
Diabetes 1 290 9 8 7 7 6 5 4 4 3 230 
300 9 8 7 7 6 6 5 4 3 240 
250 
Average 2-yr Risk in Men With CVD 
2-yr 
Tota l  Probability Age Probability 
Points (%.) (yr) (%) 
0 2 
2 2 
4 3 
6 5 
8 7 
10 10 
12 14 
14 20 
16 28 
18 37 
20 49 
22 63 
24 77 
35-39 <1 
40-44 8 
45-49 10 
50-54 11 
55-59 12 
60-64 12 
65-69 14 
70-74 14 
CVD = cerebrovascular disease; other abbreviations as in Table 1. 
Points 
exertional anginal pain symptoms. Furthermore, the prognos- 
tic weight for typical angina contributes more than age, gender 
or ECG conduction defects (17). 
In patients with established angina, the characteristics of
the anginal symptoms can be related to subsequent risk of an 
event (17). This risk has been quantified, characterizing the 
course as stable or progressive and measuring the frequency of 
the discomfort and the presence of ST segment changes on the 
ECG (32). An angina score has been constructed that quanti- 
fies the probability of death as a function of the characteriza- 
tion of the angina and the recent history of myocardial 
infarction. Table 5 provides the relative risk associated with 
each chest pain characteristic; these values (points) are used in 
the calculation of 1-year mortality (shown later in Table 7). 
Depending on the variable, this risk may be additive or 
multiplicative when more than one characteristic is present. 
Unstable angina. Patients with unstable angina constitute 
about 10% of all initial presentations with coronary artery 
disease. A recent clinical practice guideline (24) has synthe- 
sized the published reports into empirical guidelines for risk 
stratification of patients with unstable angina. The clinical 
criteria for classification as well as for stratification of short- 
term risk of death or nonfatal myocardial infarction in patients 
with unstable angina are shown in Table 6. 
Rest ECG. The presence of the changes from a prior 
myocardial infarction or a conduction disturbance on the 
routine 12-lead ECG, or both, provides independent prognos- 
tic information. In particular, left bundle branch block and 
nonspecific intraventricular conduction delay provide greater 
prognostic accuracy, but right bundle branch block and hemi- 
blocks also provide independent predictive information (33). 
Congestive heart failure. Patients with congestive heart 
failure account for over 400,000 new ischemic events each year, 
including at least 200,000 deaths. In particular, patients with 
heart failure with left ventricular dysfunction (ejection fraction 
<0.40) have a reduced survival that has been shown in multiple 
large clinical trials (34-36); survival is inversely proportional to 
the degree of functional impairment. In the CASS experience, 
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Figure 1. Risk of future cardiac events as a function of time since the 
event or procedure. MI = myocardial nfarction. 
the 12-year survival was dramatically affected by the presence 
of heart failure at baseline (16). Survival was 81% for no heart 
failure, 71% for functional class I, 54% for class II, 25% for 
class III and 11% for class IV. Over 50% of patients in 
functional class IV die within 5 years; a large majority of these 
deaths are sudden (34-37). In addition to symptomatic heart 
failure, the presence of an $3 gallop on physical examination r
cardiomegaly onthe chest radiograph adds independent prog- 
nostic information. 
Peripheral and cerebral vascular disease. Angiographically 
significant and often severe coronary artery disease is prevalent 
among patients with aortic and peripheral atherosclerosis 
(38-41). Even in the presence of a given extent of coronary 
artery disease and left ventricular dysfunction, patients with 
clinical manifestations of peripheral vascular disease have a 
higher isk of death than patients without peripheral vascular 
disease (18). Of 30,411 patients with coronary disease followed 
at the Duke Databank, annual mortality for patients with a 
concomitant history of cerebrovascular disease is 5.1%, a rate 
some 25% higher than for those with coronary artery disease 
alone. 
Figure 2. Risk of occlusion due to thrombosis or mechanical obstruc- 
tion as a function of time from coronary artery bypass urgery. 
Reprinted from Smith et al. (26), with permission. 
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Table 5. Relative Risk Based on Anginal Characteristics 
1-yr Mortality 
Characteristic Points Rate (%)* 
Nonanginal pain 3 0.4 
Atypical angina 25 0.8 
Stable angina 41 1.3 
Progressive 46 1.5 
Unstable 51 1.7 
*For a 60-year old patient with no comorbid conditions. 
Summary risk. These features of the clinical history and 
physical examination can be summarized asshown in Table 7. 
These data are analogous to those in Table 1 from Framing- 
ham, except hat clinical features of patient characterization 
predominate. 
Diagnostic and Prognostic Testing 
At the time of risk assessment, a test to evaluate functional 
capacity or the response to a provocation such as exercise or 
pharmacologic stress may be included. Regardless of other 
available options, the history, physical examination and ECG 
remain the cornerstones of any prognostic eval" tion. In 
addition, the physician and patient may choose J obtain 
routine stress testing, provocative testing with imaging for 
ischemia or left ventricular function, rest imaging for left 
ventricular function or coronary angiography with left ven- 
triculography. The goal of this section is not to recommend any 
specific strategy of testing, but to provide information about 
prognosis if a test is chosen or may be available from a recent 
previous evaluation. 
Left ventricular function. Rest left ventricuiar function is 
a powerful determinant of subsequent patient outcome. The 
importance of the rest ejection fraction by radioactive tech- 
niques was confirmed for chronic stable angina in the Veterans 
Administration Cooperative Study (42) and the CASS study (16) 
and for acute myocardial infarction in the Multicenter Postin- 
farction Research study groups (43) and others (44). These 
studies consistently have found a nonlinear elationship be- 
tween systolic left ventricular function measured by left ven- 
tricular ejection fraction and death; the risk is particularly 
accelerated with each decrease in ejection fraction below 40% 
(Fig. 3) (45). 
Noninvasive testing modalitics. For many patients with 
coronary artery disease, stress testing with exercise or pharma- 
cologic agents can provide a useful and powerful supplement 
to the initial clinical evaluation. However, limitations of the 
noninvasive testing literature include a paucity of prospective 
patient series and insufficient sample sizes. Up to one-half of 
all noninvasive testing reports are based on sample sizes 
insufficient to test their primary hypothesis. Additionally, 90% 
of all published reports are nonprospective s ries and subject 
to selection and reviewer biases. It is often impossible to 
compare results of case series because of the major differences 
in baseline characteristics between patients referred for one 
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Tab le  6. Risk Classification for Patients With Unstable Angina 
Low Risk (<1%) Intermediate Risk (]-4%) High Risk (>4%) 
No intermediate risk features but must have any of 
the following: 
Increased angina frequency, severity or duration 
Angina provoked at a lower threshold 
New-onset angina with onset 2 wk to 2 mo 
before presentation 
No high risk features but must have any of the 
following: 
Prolonged (->20 min) ongoing rest angina, now 
resolved with moderate or high likelihood 
of CAD 
Rest angina (->20 min or relieved with rest or 
SL NTG) 
Nocturnal angina 
Angina with dynamic T wave changes 
New-onset CCSC III or IV angina in past 2 wk 
with moderate to high likelihood of CAD 
Pathologic Q waves or rest ST depression 
<1 mm in multiple lead groups (anterior, 
inferior, lateral) 
Age >65 yr 
At least one of the following features must be present: 
Prolonged (->20 min), ongoing rest pain 
Pulmonary edema, ischemic n origin 
Angina at rest with dynamic ST changes (1+ mm) 
Angina with new or worsening MR murmur 
Angina with $3 or new/worsening rales 
Angina with hypotension 
CAD = coronary artery disease; CCSC = Canadian Cardiovascular Society classification; MR= mitral regurgitation; SL NTG = sublingual nitroglycerin. 
testing modality versus another. The most commonly cited 
comparative stimates, sensitivity and specificity, are often 
derived from small subgroups of the study populations. Details 
about patients who did not proceed to cardiac catheterization 
or those who were lost to follow-up (i.e., ascertainment bias) 
are frequently ill-described. In summary, based upon the 
results of a thorough synthesis of published noninvasive data, it 
is difficult to know the true diagnostic or prognostic accuracy of 
many noninvasive testing modalities used in current practice. 
Tab le  7. Risk of Mortality at 1 Year: Clinical History Variables 
1. Find Points for Each Risk Factor: 
Age Angina Comorbid 
(yr) Points (pain type) Points Factor Points* 
20 0 Nonanginal pain 3 CVD 20 
30 13 Atypical angina 25 PVD 23 
40 25 Typical angina Diabetes 20 
50 38 Stable 41 Prior MI 17 
60 50 Progressive 46 Hypertension 8 
70 62 Unstable 51 Mitral regurgitation 
80 75 Mild 19 
90 88 Severe 38 
100 100 
2. Sum Points for All Risk Factors: 
- - + - - +  
Age Pain score Comorbidity Point total 
3. Look Up Risk Corresponding to Point Total: 
Probability of 
Total Points 1-yr Death Total Points 
Probability of 
1-yr Death 
84 1% 199 30% 
106 2% 211 40% 
120 3% 220 50% 
136 5% 229 60% 
160 10% 
184 20% 
*Zero points for each "no." CVD = cerebrovascular disease; MI = 
myocardial infarction; PVD = peripheral vascular disease. 
Exercise ECG. A standard treadmill test is routinely per- 
formed in patients who are not taking digoxin or other drugs 
that can affect ST segment analysis, who are able to exercise 
and who have a normal rest ECG. Studies have shown that the 
response to exercise permits assessment of the severity of 
underlying coronary artery disease and the risk of death. 
Several features have been associated with adverse prognosis: 
duration of exercise, number of leads with and amount of ST 
depression, exercise-induced angina, maximal exercise heart 
rate, drop in systolic blood pressure and ventricular arrhyth- 
mia. A treadmill score was developed that uses three of these 
variables to predict 4-year survival in patients with suspected 
coronary artery disease (46). The treadmill score may be 
calculated by the following formula: 
Duration of exercise (rain) 
- [Maximal ST segment deviation (mm) during or after 
exercise x 5] 
- (Treadmill angina index x 4), 
Figure 3. Risk of mortality at 2 years as a function of left ventricular 
ejection fraction. Reprinted from Morris (45), with permission. 
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Table 8. Survival at Four Years According to Treadmill Score 
Low Risk Intermediate Risk High Risk 
Treadmill score More than +5 -10 to +4 Below -10 
Survival 
Inpatients 98% 92% 71% 
Outpatients 99% 95% 79% 
where the angina index is as follows: no angina during exer- 
cise = 0; nonlimiting angina = 1; exercise-limiting angina = 2. 
The 4-year survival of patients in low, intermediate and high 
risk categories i shown in Table 8. 
Ambulatory ECG monitoring. Ambulatory ischemia has also 
been shown to be an independent, incremental marker of risk 
in patients with stable and unstable angina as well as in 
post-myocardial nfarction patients (47-49), although inade- 
quate numbers of patients have been evaluated to allow 
specific depiction of risk level in a figure. 
Stress imaging techniques. Patients with widespread ST 
depression (> 1 mm), left ventricular hypertrophy, intraventric- 
ular conduction defects (e.g., left bundle branch block) or 
pre-excitation are more often referred for imaging. The type of 
imaging agent may allow further definition of dyssynergy or left 
ventricular limitations or assessment of flow limitations in one 
or more lesions. 
Stress myocardial perfusion imaging. Transient perfusion 
defects that "fill in" on the delayed images are consistent with 
exercise-induced myocardial ischemia. A high risk scan may be 
defined as the presence of multiple perfusion defects, in- 
creased lung uptake or left ventricular dilation. The presence 
of multiple perfusion defects is more closely associated with 
multivessel disease. Scarred or fixed defects characteristically 
reflect infarcted tissue, although they may become ischemic 
after reinjection i  some 30% of thallium-201-tested patients. 
Although the data have been derived from small samples and 
may be considered observational, a synthesis of research 
results reveals that patients with high risk scans are more likely 
to have multivessel disease and worse survival. The accuracy of 
peffusion imaging may be further enhanced by the use of 
quantitative single-photon emission computed tomographic 
(SPECT) imaging or by the use of new imaging agents, such as 
technetium-99m sestamibi. Technetium-99m sestamibi pro- 
vides enhanced resolution, with similar diagnostic and prog- 
nostic accuracy, compared with thallium-201 imaging. Wall 
motion and left ventricular function can also be simultaneously 
obtained. It may be particularly useful for female or obese 
patients, whose breast issue may interfere with imaging inter- 
pretation. Although there are recognized imaging and radio- 
tracer differences between thallium-201 and technetium-99m, 
predictive modeling with technetium-99m has demonstrated 
that the presence of an exercise sestamibi perfusion defect 
independently predicts 1-year death or nonfatal myocardial 
infarction in patients with stable coronary artery disease (50). 
Prediction of risk with noninvasive testing. Although con- 
siderable information has been accrued on prediction of risk 
based upon a patient's clinical risk profile, limited data are 
available to the clinician on the likelihood of disease or 
subsequent cardiac death as determined by stress myocardial 
perfusion imaging. Nomograms for the prediction of signifi- 
cant coronary disease (at least one artery with 70% stenosis), 
severe disease (three-vessel or left main involvement) and 
cardiac death are presented in Figures 4 to 6. The level of 
incremental risk of severe disease provides insight into the use 
of these technologies topredict mortality. 
Figures 4 and 5 provide predictive information derived 
from stress myocardial perfusion imaging. These estimates are 
based on a group of 1,800 patients undergoing cardiac athe- 
terization and exercise or pharmacologic stress SPECT imag- 
ing from 1991 to 1995 at Duke University Medical Center. 
These nomograms allow a physician to estimate the incremen- 
tal value of testing in populations that have different pretest 
clinical risk levels. Overall, stress myocardial perfusion imaging 
Figure 4. Nomogram for predic- 
tion of significant coronary artery 
disease (CAD), defined as at least 
one vessel with 70% stenosis, with 
stress myocardial perfusion imag- 
ing. 
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Figure 5. Nomogram for predict ion 
of severe coronary artery disease 
(CAD), defined as three-vessel or
left main coronary artery disease, 
with stress myocardial perfusion im- 
aging. 
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may contribute as much as 40% of the predictive information 
for significant coronary artery disease (Fig. 4) and 20% of the 
predictive information for severe disease (Fig. 5). 
Since testing is not expected to be of value in patients who 
have low pretest risk, pretest probability begins only in patients 
with a moderate to high likelihood of coronary artery disease. 
However, perfusion imaging likewise may not be helpful for 
patients who have a very high pretest clinical risk profile. As 
shown in Figure 4, if the pretest risk estimate xceeds 90%, the 
risk of disease increases from 70% to 90%. This incremental 
information might not be sufficient o alter patient manage- 
ment and thus would not be clinically meaningful. It should be 
noted that these estimates are based on catheterized patients; 
they may overestimate risk as compared with patients evalu- 
ated in a nuclear laboratory. 
Pharmacologic stress perfusion imaging. In patients unable 
to perform maximal stress tests, a number of pharmacologic 
stressors may be used, including dipyridamole, adenosine and 
dobutamine. No evidence xists that one is superior, although 
dipyridamole has been used for more than 10 years and has a 
more substantial body of literature supporting its effectiveness 
as a diagnostic and prognostic tool. Risk stratification with 
dipyridamolc-thallium-201 perfusion imaging (51) indicates 
that the presence of a perfusion defect is able to provide 
independent prognostic information. Dobutamine stress echo- 
cardiography has become an increasing popular method for 
risk stratification (52,53). Dobutamine-induced ventricular 
wall motion abnormalities have been significantly associated 
with myocardial viability and restenosis in several observa- 
tional patient series (53). In patients undergoing vascular 
surgery, the presence of new or worsening dyssynergy was 
associated with a 5- to 14-fold increase in risk of subsequent 
death or reinfarction (52). 
Exercise radionuclide angiography. Regardless of the radio- 
nuclide technique (first-pass or gated), a review of the pub- 
lished reports on exercise radionuclide angiography reveals 
that exercise ejection fraction is the best univariate and 
multivariable predictor of a cardiac event (54-60). In one 
large series, the continuous relationship between the risk of 
death and exercise jection fraction had the same shape as the 
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Figure 6. Nomogram for predict ion 
of cardiac death at 1 year with exer- 
cise radionucl ide angiography. 
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Table 9. Coronary Artery Disease Prognostic Index 
Prognostic Weight 5-yr Mortality 
Extent of CAD (0-100) Rate (%)* 
1-vessel disease, 75% 23 7 
>l-vessel disease, 50-74% 23 7 
1-vessel disease, ->95% 32 9 
2-vessel disease 37 12 
2-vessel disease, both ->95% 42 14 
1-vessel disease, ->95% proximal LAD 48 17 
2-vessel disease, ->95% LAD 48 17 
2-vessel disease, ->95% proximal LAD 56 21 
3-vessel disease 56 21 
3-vessel disease, ->95% in at least 1 63 27 
3-vessel disease, 75% proximal LAD 67 33 
3-vessel disease, ->95% proximal LAD 74 41 
*Assuming medical treatment only. CAD = coronary artery disease; LAD = 
left anterior descending coronary artery. 
mortality-rest ejection fraction relationship, but the exercise 
ejection fraction was a more powerful predictor (56). Multiple 
studies have shown that patients with exercise jection frac- 
tions <40% have very low rates of survival (56,59). The 
summary odds of a cardiac event are fourfold higher for 
patients with an abnormal peak radionuclide angiogram versus 
those with a normal examination (61). In patients with a 
normal ejection fraction, the presence of ventricular wall 
motion or functional abnormalities during exercise has been 
associated with a worsening 4-year survival (61). 
Figure 6 details the results of 780 patients undergoing ated 
equilibrium radionuclide angiography at Duke University. In 
this model, 1-year prognosis i  best predicted by a combination 
of peak bicycle work load, exercise jection fraction and the 
patient's pretest clinical risk. In this case, the combination of 
ejection fraction and functional capacity data provides ubstan- 
tial improvement over clinical history estimates. 
Exercise echocardiography. Stress echocardiography as 
been reported to have improved iagnostic accuracy over the 
exercise ECG alone. Stress echocardiography is not affected by 
breast attenuation (as is perfusion imaging), and it allows the 
evaluation of wall motion in multiple planes. 
Extent of coronary artery disease. One of the most impor- 
tant prognostic factors in patients with coronary artery disease 
is the extent and severity of underlying coronary artery disease 
(62). A number of prognostic indexes have been developed 
that relate the severity and extent of coronary artery disease to 
the subsequent risk of adverse outcomes. The simplest depic- 
tion of the extent of disease into one-vessel, two-vessel, 
three-vessel or left main disease has provided a useful clinical 
shorthand; recent long-term follow-up from the CASS study 
indicates the continued utility of this simple classification. 
Further evaluations have led to the clinically obvious conclu- 
sion that proximal coronary stenoses are more important for 
prognosis than distal coronary lesions. This concept is the basis 
of the "jeopardy score" (63), in which the prognostic signifi- 
cance of lesions is weighted as a function of location within the 
vessel. 
More recently, Mark et al. (64) proposed a new prognostic 
coronary artery disease index (Table 9). This hierarchical index 
takes into account information about the lesion severity and 
location with prognostic weights ranging from 0 (no coronary 
artery disease) to 100 (95% left main stenosis). The index was 
developed by specifically analyzing the relationship between 
the location of the lesions and the risk of cardiac death in 
medically treated patients. This index is able to stratify patients 
who appear to have a substantial survival benefit from revas- 
cularization strategies (64-66). 
Figure 7 depicts a nomogram that integrates information 
from the history, physical examination, and cardiac catheter- 
ization findings for prediction of the risk of death. 
Figure 7. Nomogram for prediction of 
5-year survival from clinical, physical exam- 
ination and cardiac atherization fi dings. 
Asymp = asymptomatic; CAD = coronary 
artery disease; MI = myocardial infarction; 
Symp = symptomatic. 
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Summary and Future Work 
As detailed in this task force report, considerable observa- 
tional and clinical trial data have been accrued to identify risk 
markers from the initial examination and from a variety of 
noninvasive test results. Substantial information is available 
regarding the risk of future coronary artery disease vents in 
populations without clinically evident coronary artery disease, 
based on risk factors readily available from simple evaluations 
(age, blood pressure) and laboratory measurements (lipids). 
Less is known about the complex interplay of symptoms, risk 
factors, coronary anatomy and results of additional testing in 
patients who have established coronary artery disease. A case 
in point is the incremental impact of noninvasive test results 
beyond the information obtained from a patient's clinical 
history. A negative test may provide a great deal of reassurance 
to the patient as well as information regarding enhanced 
survival. Further, patients with a high risk stress test (e.g., 
multiple perfusion defects, ejection fraction <0.35) have worse 
survival. However, noninvasive testing is of value only if it adds 
substantially to the clinical history and thus would improve 
clinical decision making. Although some information is avail- 
able to document the independent prognostic value of nonin- 
vasive testing beyond the initial clinical examination, integra- 
tion of this information in real time to determine when further 
testing may be useful or when it may be unhelpful in further 
risk stratification remains a challenge (56,61,67). 
The incremental cost of additional prognostic information 
is another issue that merits investigation. In many circum- 
stances, a less expensive valuation may provide similar infor- 
mation. The value of a simple clinical prediction rule should 
not be underestimated. Clinically based models have been 
equally able to predict outcome or the results from noninvasive 
testing, or both, thus obviating the need for further risk 
stratification from subsequent procedures (18,62,68). There 
are many unresolved issues regarding not only the indepen- 
dence of risk measures but also their clinical relevance in 
populations where indecision is greatest. These issues, which 
affect daily clinical decision making, must be addressed in the 
future with more rigorous methodologies. 
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